Optimal duration of additional therapy after favorable response to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised trial

被引：0
|
作者：
Enomoto, Masaru [1 ]
Tamori, Akihiro [1 ]
Toyama, Madoka [1 ]
Hayashi, Kohmoto Takehiro [1 ]
Morikawa, Hiroyasu [1 ]
Jomura, Hisato [1 ]
Habu, Daiki [1 ]
Sakaguchi, Hiroki [1 ]
Takeda, Tadashi [1 ]
Shiomi, Susumu [2 ]
Nishiguchi, Shuhei [3 ]
Kawada, Norifumi [1 ]
机构：
[1] Osaka City Univ, Sch Med, Dept Hepatol, Osaka, Japan
[2] Osaka City Univ, Sch Med, Dept Nucl Med, Osaka, Japan
[3] Hyogo Med Univ, Dept Internal Med, Osaka, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A250 / A250
页数：1
相关论文
共 50 条
  • [1] Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial
    Enomoto, Masaru
    Tamori, Akihiro
    Kohmoto, Madoka Toyama
    Hayashi, Takehiro
    Morikawa, Hiroyasu
    Jomura, Hisato
    Sakaguchi, Hiroki
    Habu, Daiki
    Kawada, Norifumi
    Shiomi, Susumu
    Nishiguchi, Shuhei
    HEPATOLOGY RESEARCH, 2008, 38 (09) : 954 - 959
  • [2] Efficacy of lamivudine in HBeAg-negative chronic hepatitis B
    Rizzetto, M
    JOURNAL OF MEDICAL VIROLOGY, 2002, 66 (04) : 435 - 451
  • [3] Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B
    Rizzetto, M
    Tassopoulos, NC
    Goldin, RD
    Esteban, R
    Santantonio, T
    Heathcote, EJ
    Lagget, M
    Taak, NK
    Woessner, MA
    Gardner, SD
    JOURNAL OF HEPATOLOGY, 2005, 42 (02) : 173 - 179
  • [4] Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    Lai, CL
    Shouval, D
    Lok, AS
    Chang, TT
    Cheinquer, H
    Goodman, Z
    DeHertogh, D
    Wilber, R
    Zink, RC
    Cross, A
    Colonno, R
    Fernandes, L
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10): : 1011 - 1020
  • [5] Lamivudine therapy in HBeAg negative chronic hepatitis B patients
    Guclu, E.
    Batirel, A.
    Ince, N. Koc
    Ogutlu, A.
    Durmaz, Y.
    Ozdemir, D.
    Geyik, M. F.
    Karabay, O.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 444 - 444
  • [6] Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
    Di Marco, V
    Marzano, A
    Lampertico, P
    Andreone, P
    Santantonio, T
    Ahnasio, PL
    Rizzetto, M
    Craxì, A
    HEPATOLOGY, 2004, 40 (04) : 883 - 891
  • [7] Efficacy of the treatment of HBeAg-negative chronic hepatitis B patients with lamivudine: Results of 12 month therapy
    Seliverstova, T
    Isakov, V
    Bogomolov, P
    Mironova, O
    Pavlova, T
    Tsodikov, G
    Guschin, A
    HEPATOLOGY, 2002, 36 (04) : 637A - 637A
  • [8] HBSAG SEROCOVERSION UNDER LAMIVUDINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Seven, Gulseren
    Idilman, Ramazan
    Bozkus, Yusuf
    Cinar, Kubilay
    Kabacam, Gokhan
    Yakut, Mustafa
    Bozdayi, A. Mithat
    Yurdaydin, Cihan
    HEPATOLOGY, 2010, 52 (04) : 545A - 546A
  • [9] Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia
    Bozkaya, H
    Yurdaydin, C
    Idilman, R
    Tüzün, A
    Cinar, K
    Erkan, Ö
    Bozdayi, AM
    Erden, E
    Uzun, Y
    Cetinkaya, H
    Uzunalimoglu, Ö
    ANTIVIRAL THERAPY, 2005, 10 (02) : 319 - 325
  • [10] Progress in HBeAg-negative chronic hepatitis B therapy
    Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1 (1): : 11 - 11
12345